Treatment
Recommendation 4.3
➤ Endocrine therapy for men with advanced or metastatic, hormone
receptor-positive, HER2-negative breast cancer may be sequenced
as in women. (Moderate Recommendation; FC-L)
Recommendation 5
➤ Targeted therapy guided by HER2, PDL-1, PIK3CA, and germline
BRCA mutation status may be used in the treatment of advanced
or metastatic male breast cancer using the same indications and
combinations that are offered to women. (Strong Recommendation;
FC-L)
Note: Targeted therapy based on hormone receptor status is addressed in
Recommendations 4.1 – 4.3
Recommendation 6.1
➤ Management of endocrine therapy toxicity is similar to the approach
used for women. (Moderate Recommendation; FC-L)
Recommendation 6.2
➤ Testosterone/androgen supplementation should not be used by men
with breast cancer. (Moderate Recommendation; FC-L)
Recommendation 7
➤ Physicians should counsel patients about the symptoms of
recurrence including new lumps, bone pain, chest pain, dyspnea,
abdominal pain, or persistent headaches. The risk of breast cancer
recurrence continues through 15 years after primary treatment
and beyond. Continuity of care for patients with breast cancer is
recommended and should be performed by a physician experienced
in the surveillance of patients with cancer and in breast examination,
including the examination of irradiated breasts. (Moderate
Recommendation; FC-L)
Recommendation 8
➤ Ipsilateral annual mammogram should be offered to men
with a history of breast cancer treated with lumpectomy, if
technically feasible, regardless of genetic predisposition. (Strong
Recommendation; FC-L)
